Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

These are the latest findings of Valuates Reports (Karnataka, India), a market research company.

dPCR is a laboratory technique for making multiple copies of a specific piece of DNA from a sample with very small amounts of DNA. These fragments of DNA can be amplified and detected using PCR. It also provides for precise and sensitive nucleic acid measurement. It's also employed for absolute quantification and minority sequence analysis. The rise in the incidence of infectious diseases, as well as increased knowledge and acceptance of tailored treatments, are driving the expansion of the dPCR market. Furthermore, technological developments as a result of increased funding for R&D activities are likely to drive the dPCR market expansion during the forecast period.

The growth of the digital PCR market is expected to be fueled by the rising prevalence of infectious diseases and genetic disorders. As a result of its increasing use in the diagnosis of major infectious diseases and genetic disorders, the market for genomic analysis tools has gradually expanded over the last decade.

dPCR is more sensitive and clinically useful than real-time fluorogenic quantitative PCR. The typical PCR system is done by several microunits in dPCR, which greatly increases the PCR system's tolerance to inhibitors. Traditional PCR has a sensitivity of up to 1%, whereas dPCR has a sensitivity of up to 0.1%, and in certain cases as low as 0.001%, making it a perfect technique for trace DNA identification, uncommon mutation detection, and notably circulating tumor DNA detection. Furthermore, dPCR has been technologically upgraded to become a more operational and compatible tool, with highly understandable two-dimensional data. These advantages offered by dPCR are expected to drive market growth.

Even when only a small volume of sample is available, dPCR still achieves good accuracy, especially when identifying difficult-to-take samples or samples with the damaged nucleic acid. Clinical samples should be amplified when performing other genomic analyses, such as comparative genomic hybridization (CGH) chip or next-generation sequencing (NGS), to provide a large enough volume, but dPCR can be performed with a small number of samples, yielding reliable results by eliminating the error generating from preamplification. Thus, the ability to produce accurate results even with smaller sample size is increasing the adoption of dPCR, which in turn, is expected to drive market growth.

There have been numerous studies published since the COVID-19 pandemic in favor of dPCR for COVID-19 testing. Due to several variables such as higher sensitivity of ddPCR (Droplet Digital PCR), absence of inhibition from sample types, and simplicity of comprehending the data, there has been a considerable increase in the demand for ddPCR equipment and SARS-CoV-2 kits. Thus, the COVID-19 outbreak is expected to further propel the growth of the dPCR market.

Based on technology, the ddPCR segment dominated the dPCR market in 2020 and will maintain its lead over the forecast period. Its ability to accurately estimate DNA molecules with each drop made the ddPCR technique the leading revenue contributor to the dPCR market in 2020. Furthermore, a crucial component of the ddPCR technology is enormous sample splitting, which has increased its demand. Based on product type, the software & services segment is projected to exhibit the fastest growth during the forecast period, as software helps to improve the efficiency of management of dPCR data. Thus, there has been an increase in the demand for these products, thereby propelling the growth of the dPCR market.

Geographically, North America was the leading revenue contributor to the global dPCR market in 2020 and is expected to maintain its dominant position throughout the forecast period. This can be attributed to the region's well-developed healthcare industry, as well as the existence of prominent molecular diagnostics firms and an increase in the number of patients receiving tailored medicines. However, the Asia-Pacific dPCR market is expected to register the fastest CAGR of almost 14.50% during the forecast period due to an increase in the number of patients suffering from chronic diseases and improvement in healthcare facilities in the region, thereby providing lucrative opportunities for molecular diagnostics players.

Related Links:
Valuates Reports